AMR Davos Compact 2025

2 the present burden of antimicrobial resistance, with the aim to reduce the global deaths associated with bacterial antimicrobial resistance by 10 % by 2030 against the 2019 baseline of 4.95 million deaths, and undertake to address the multifaceted and cross- cutting nature of antimicrobial resistance.” 6 The Member States attending and endorsing the 4th Ministerial High -Level Global Conference on AMR in November 2024 resolved to translate the Political Declaration into practical commitments (the “Jeddah Commitments”) for urgent actions. 7 For their part, G7 leaders assured that they “will spare no efforts to continue addressing this silent pandemic,” 8 and G20 leaders promised to “implement and prioritize tackling AMR following the One Health approach ”.9 Building on these commitments and r ecognizing th at their achievement depends on the mobilization of significant financial resources from both public and private actors, we, the undersigned founding partners of the Unified Coalition for the AMR Response (UCARE) – representing key governments from the G7, EU, G20 and G77, the Quadripartite Joint Secretariat on AMR (QJS) composed of the Food and Agriculture Organization (FAO) of the United Nations, the United Nations Environment Programme (UNEP), the World Health Organization (WHO) and the World Organi sation for Animal Health (WOAH), alongside leading private sector entities including pharmaceutical companies, healthcare providers, food industry leaders, financial institutions, philanthropic organizations, and asset managers and owners such as insurance companies and pension funds – pledge to translate these government ambitions into concrete opportunities for public- private collaborations. Multiple market failures hinder the mobilization of adequate private resources to control AMR. For example, when international guidelines such as WHO AWaRe (Access, Watch, Reserve) classification recommend that last-resort antibiotics should be reserved only for a limited number of patients to prevent a rapid decline in their effectiveness, this practice limits the return on investment for antibiotic innovation. In argi -food systems, the immediate costs of implementing best practices outweigh the short- term economic benefits for farmers. Th ese realities hinder the development and accessibility of essential innovation s needed to combat AMR and ensure food security. Addressing AMR requires collective action supported by robust market -based economic incentives and sustainable financial mechanisms. Many countries face significant resource constraints and competing development priorities, such as food security, poverty reduction, and climate change, which limit their capacity to adequately invest in reduction of antimicrobial use and AMR mitigation. Without innovative solutions that align global and national interests, the financial burden of addressing AMR will remain a significant barrier. Under the aegis of UCARE, government and philanthropic organizations commit to create the right conditions for private sector investments to address AMR. In return, global and local businesses commit to allocate significant financial resources to fund and deploy innovative solutions against drug-resistant infections. To achieve its objectives, UCARE will work with , and compl ement the efforts of, other international initiatives , such as the Global Leaders Group on AMR ( GLG) , the AMR